



1615

PTO/SB/21 (08-03)

Approved for use through 08/30/2003. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/607,530
Filing Date	June 26, 2003
First Named Inventor	Dunning et al.
Art Unit	1615
Examiner Name	
Attorney Docket Number	53001AUSM1

Total Number of Pages in This Submission

3 plus  
references

and Search Report

### ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please Identify below): PTO-1449 w/references Return Post Card Search Report
<div>Remarks</div>		

### SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Ronald S. Hermenau, Registration No. 34,620
Signature	<i>Ronald S. Hermenau</i>
Date	12/2/03

### CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Mary Ann Flores		
Signature	<i>Mary Ann Flores</i>	Date	12/02/03

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Dunning et al. : Group Art Unit: 1615  
Application No.: 10/607,530 : Examiner: Not Known  
Filed: June 26, 2003 : Docket No. 53001AUSM1

For: Substituted Quinoline CCR5 Receptor Antagonists

Mail Stop Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with 37 CFR §1.56 and 1.97 through 1.98, applicants which to make known to the Patent and Trademark Office the references cited on the attached form PTO-1449 (copies enclosed). The references cited on the attached form PTO-1449 include references that were first cited in a foreign search report (attached) in a counterpart foreign application not more than 3 months prior to the mailing date of this IDS. As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. §1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.


Please acknowledge receipt of this Supplemental Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Respectfully Submitted,

Ronald S. Hermenau (Reg. No. 34,620)  
Patent Attorney for Applicants

Date: 12/2/03

Berlex Biosciences  
2600 Hilltop Drive  
P.O. Box 4099  
Richmond, California 94804-0099  
Telephone No. 510-669-4483  
Facsimile No. 510-262-7095  
**Customer No. 27586**

**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.

53001AUSM1

SERIAL NO.

10/607,530

APPLICANT(S)

Dunning *et al.*

FILING DATE

June 26, 2003

GROUP

1615

**U.S. PATENT DOCUMENTS**

Initial		Document Number	Date	Name	Class/ Subclass	Filing Date
	01	6,344,450	05FEB2002	Bisacchi <i>et al.</i>		07AUG2000

**FOREIGN PATENT DOCUMENTS**

Initial		Document Number	Date	Country	Translation	
					Yes	No
/	02	WO 02/072578	19SEP2002	PCT	X	
/	03	EP 1308439	07MAY2003	EP	X	
/	04	EP 0882717	09DEC1998	EP	X	
	05	FR 84902	07MAY1965	FR		X
/	06	EP 1013276	28JUN2000	EP	X	
/	07	WO 02/22599	21MAR2002	PCT	X	
/	08	WO 02/094203	28NOV2002	PCT	X	

**OTHER DOCUMENTS** (Include Author, Title, Date, Pertinent Pages, etc.)

	09	Agrawal V K <i>et al.</i> , "Antiparasitic Agents: Part VI – Synthesis of 7-Chloro-4-(4-substituted-phenylamino)- & 7-Chloro-4-(4-substituted-Piperazin-1-YL) Quinolines as Potential Antiparasitic Agents", <i>Indian Journal of Chemistry</i> , (1987) 26B:550-555.				
	10	Kireev D <i>et al.</i> , "Molecular modeling and quantitative structure-activity studies of anti-HIV-1 2-heteroarylquinoline-4-amines" <i>European Journal of Medicinal Chemistry</i> , (1995) 30:395-402				
	11	Tripathi, R.C. <i>et al.</i> , <i>Indian J. Chemistry</i> , (1995) 34:164-166 (abstract)				

**EXAMINER****DATE CONSIDERED**

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.